Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Status:
NOT_YET_RECRUITING
Trial end date:
2031-03-07
Target enrollment:
Participant gender:
Summary
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).